Human xylosyltransferase I: functional and biochemical characterization of cysteine residues required for enzymic activity.
XT-I (xylosyltransferase I) is the initial enzyme in the post-translational biosynthesis of glycosaminoglycan chains in proteoglycans. To gain insight into the structure-function relationship of the enzyme, a soluble active form of human XT-I was expressed in High Five insect cells with an apparent molecular mass of 90 kDa. Analysis of the electrophoretic mobility of the protein under non-reducing and reducing conditions indicated that soluble XT-I does not form homodimers through disulphide bridges. In addition, the role of the cysteine residues was investigated by site-directed mutagenesis combined with chemical modifications of XT-I by N-phenylmaleimide. Replacement of Cys471 or Cys574 with alanine led to a complete loss of catalytic activity, indicating the necessity of these residues for maintaining an active conformation of soluble recombinant XT-I by forming disulphide bonds. On the other hand, N-phenylmaleimide treatment showed no effect on wild-type XT-I but strongly inactivated the cysteine mutants in a dose-dependant manner, indicating that seven intramolecular disulphide bridges are formed in wild-type XT-I. The inhibitory effect of UDP on the XT-I activity of C561A (Cys561-->Ala) mutant enzyme was significantly reduced compared with all other tested cysteine mutants. In addition, we tested for binding to UDP-agarose beads. The inactive mutants revealed no significantly different nucleotide-binding properties. Our study demonstrates that recombinant XT-I is organized as a monomer with no free thiol groups and strongly suggests that the catalytic activity does not depend on the presence of free thiol groups, furthermore, we identified five cysteine residues which are critical for enzyme activity.
Institut für Laboratoriums und Transfusionsmedizin, Herz und Diabeteszentrum Nordrhein-Westfalen, Universitätsklinik der Ruhr-Universität Bochum, Georgstrasse 11, 32545 Bad Oeynhausen, Germany.
Sandra
S
Müller
Manuela
M
Schöttler
Sylvia
S
Schön
Christian
C
Prante
Thomas
T
Brinkmann
Joachim
J
Kuhn
Christian
C
Götting
Knut
K
Kleesiek
D000595:Amino Acid Sequence; D000818:Animals; D002384:Catalysis / Q000187:drug effects; D002460:Cell Line; D002809:Chondroitin Sulfates / Q000494:pharmacology; D003001:Cloning, Molecular / Q000379:methods; D003545:Cysteine / Q000737:chemistry* / Q000235:genetics / Q000502:physiology*; D004220:Disulfides / Q000378:metabolism; D004229:Dithiothreitol / Q000494:pharmacology; D004791:Enzyme Inhibitors / Q000494:pharmacology; D000939:Epitopes / Q000235:genetics; D006493:Heparin / Q000378:metabolism / Q000494:pharmacology; D006497:Heparan Sulfate / Q000494:pharmacology; D006801:Humans; D007313:Insecta / Q000166:cytology; D008301:Maleimides / Q000494:pharmacology; D008863:Microspheres; D008969:Molecular Sequence Data; D016297:Mutagenesis, Site-Directed / Q000235:genetics; D009154:Mutation / Q000235:genetics / Q000502:physiology; D010084:Oxidation-Reduction; D010430:Pentosyltransferases / Q000096:biosynthesis / Q000737:chemistry / Q000378:metabolism*; D011994:Recombinant Proteins / Q000096:biosynthesis / Q000378:metabolism; D012995:Solubility; D014530:Uridine Diphosphate / Q000378:metabolism; D000097608:UDP Xylose-Protein Xylosyltransferase
D002809:Chondroitin Sulfates; D003545:Cysteine; D004220:Disulfides; D004229:Dithiothreitol; D004791:Enzyme Inhibitors; D000939:Epitopes; D006493:Heparin; D006497:Heparan Sulfate; D008301:Maleimides; D010430:Pentosyltransferases; D011994:Recombinant Proteins; D014530:Uridine Diphosphate; D000097608:UDP Xylose-Protein Xylosyltransferase; C028525:N-phenylmaleimide